XML 20 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9
License and Development Agreements - Endo License and Development Agreement - Additional Information (Detail) (USD $)
 3 Months Ended
Mar. 31, 2015
Milestone
Mar. 31, 2014
Jan. 31, 2012
Jan. 31, 2014
Jun. 30, 2014
Revenue Recognition, Milestone Method [Line Items]          
Non-refundable payment received     $ 30,000,000bdsi_NonRefundablePaymentReceived    
Potential milestone payments on intellectual property rights 15,000,000bdsi_PotentialMilestonePaymentReceivableIntellectualProperty        
Potential payment upon filing and acceptance 10,000,000bdsi_PotentialPaymentsUponFilingAndAcceptance        
Potential milestone payment receivable upon regulatory approval 50,000,000bdsi_PotentialMilestonePaymentReceivableRegulatoryApproval        
Payment receivable on achievement of potential sales milestones 55,000,000bdsi_PaymentsReceivableOnAchievementOfPotentialSalesMilestones        
Number of potential sales milestones 4bdsi_NumberOfPotentialSalesMilestones        
Recognized up-front payment allocated to the license 15,600,000bdsi_RecognizedUpFrontPaymentAllocatedToLicense        
Recognized up-front payment to clinical trial material and development services 14,400,000bdsi_RecognizedUpFrontPaymentToClinicalTrialMaterialAndDevelopmentServices        
Upfront payment 30,000,000bdsi_UpfrontFeesAssignedToDeliverablesConsistingOfIntellectualPropertyComponentValue        
Recognition of deferred revenue 400,000us-gaap_RecognitionOfDeferredRevenue 1,200,000us-gaap_RecognitionOfDeferredRevenue      
Term of Endo Agreement 10 years        
Total rate of reimbursable contractor costs borne 50.00%bdsi_ReimbursementOfCostIncurred        
Deferred revenue recognized during the period 775,000bdsi_ResearchAndDevelopmentReimbursements 8,452,000bdsi_ResearchAndDevelopmentReimbursements      
Clinical Trials Full Enrollment [Member]          
Revenue Recognition, Milestone Method [Line Items]          
Potential milestone payment received, clinical development 20,000,000bdsi_PotentialMilestonePaymentReceivedClinicalDevelopment
/ us-gaap_RelatedPartyTransactionAxis
= bdsi_ClinicalTrialsFullEnrollmentMember		        
Number of clinical trials 2bdsi_NumberOfClinicalTrials
/ us-gaap_RelatedPartyTransactionAxis
= bdsi_ClinicalTrialsFullEnrollmentMember		        
Clinical Trials One [Member]          
Revenue Recognition, Milestone Method [Line Items]          
Potential milestone payment received, clinical development       10,000,000bdsi_PotentialMilestonePaymentReceivedClinicalDevelopment
/ us-gaap_RelatedPartyTransactionAxis
= bdsi_ClinicalTrialsOneMember		  
Clinical Trials Two [Member]          
Revenue Recognition, Milestone Method [Line Items]          
Potential milestone payment received, clinical development         10,000,000bdsi_PotentialMilestonePaymentReceivedClinicalDevelopment
/ us-gaap_RelatedPartyTransactionAxis
= bdsi_ClinicalTrialsTwoMember
Endo Agreement [Member]          
Revenue Recognition, Milestone Method [Line Items]          
Total rate of reimbursable contractor costs borne 50.00%bdsi_ReimbursementOfCostIncurred
/ us-gaap_TypeOfArrangementAxis
= bdsi_EndoLicenseAndDevelopmentAgreementMember		        
Reimbursement rate of costs by Endo to the company as per agreement 100.00%bdsi_PercentageOfReimbursementExpenses
/ us-gaap_TypeOfArrangementAxis
= bdsi_EndoLicenseAndDevelopmentAgreementMember		        
Percentage of credit against potential future milestones 50.00%bdsi_PercentageOfCreditAgainstPotentialFutureMilestone
/ us-gaap_TypeOfArrangementAxis
= bdsi_EndoLicenseAndDevelopmentAgreementMember		        
Deferred revenue from research and development activities $ 800,000bdsi_DeferredRevenueResearchAndDevelopment
/ us-gaap_TypeOfArrangementAxis
= bdsi_EndoLicenseAndDevelopmentAgreementMember